On today's Your Call, we'll have a conversation about two recent Supreme Court rulings. One deals with brand name companies paying competitors to delay the introduction of cheaper versions of their drugs. The second ruling shields manufacturers from liability for defective medicines. So what do the recent rulings mean for those of us who take generic drugs? It's Your Call, with Rose Aguilar and you.
Emily Rusch, State Director at CalPIRG and consumer advocate. Her areas of focus include making healthcare more affordable and accessible.
Jerry Avorn, Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham Young Women's Hospital. He studies the effects of prescription drugs and policy surrounding them. He is the author of Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, now in its 11th printing.
CalPIRG: Top Twenty Pay-for-Delay Drugs
NYTimes: Healing the Overwhelmed Physician
Resources for understanding your medications:
Non-Profit drug information: RXfacts.org